Malatya Education and Research Hospital, Department of Neurology, Malatya, Turkey.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):447-454. doi: 10.26355/eurrev_202101_24413.
Multiple sclerosis (MS) is a demyelinating, chronic, and progressive autoimmune disease of the central nervous system that causes the loss of axons and grey matter, and has a high prevalence in young female patients. Fingolimod is an oral treatment agent that acts by blocking the passage of the T lymphocytes responsible for the pathogenesis of MS from lymphoid tissue into the peripheral blood. We aimed to research the effects of menstrual cycles on leukocytes and lymphocyte levels in RRMS (relapsing-remitting MS) patients who received fingolimod treatment.
This study was performed to determine the most suitable phase of the menstrual cycle in patients with RRMS for follow-up assessment of lymphopaenia levels after fingolimod treatment. The study population consisted of 41 RRMS patients receiving fingolimod therapy and 33 healthy women of reproductive age. Complete blood counts were performed in three different phases of the menstrual cycle, and the two groups were compared. Variability in the total leukocyte, lymphocyte, and neutrophil immune cell numbers between cycles was examined.
The results indicated that total leukocyte, neutrophil, and lymphocyte levels were decreased in RRMS patients receiving fingolimod treatment, but these changes were not related to the phase of the menstrual cycle. In our study, leukocyte levels in healthy individuals were significantly lower in the proliferative phase than in other phases.
The results indicated that lymphocyte monitoring in RRMS patients receiving fingolimod treatment can be performed at any stage of the menstrual cycle.
多发性硬化症（MS）是一种脱髓鞘、慢性和进行性的中枢神经系统自身免疫性疾病，会导致轴突和灰质丢失，且在年轻女性患者中发病率较高。芬戈莫德是一种口服治疗药物，通过阻止负责 MS 发病机制的 T 淋巴细胞从淋巴组织进入外周血来发挥作用。我们旨在研究月经周期对接受芬戈莫德治疗的 RRMS（复发缓解型 MS）患者白细胞和淋巴细胞水平的影响。
本研究旨在确定 RRMS 患者在接受芬戈莫德治疗后淋巴细胞减少水平随访评估的最适月经周期阶段。研究人群包括 41 名接受芬戈莫德治疗的 RRMS 患者和 33 名生育期的健康女性。在三个不同的月经周期阶段进行全血细胞计数，并对两组进行比较。检查周期之间总白细胞、淋巴细胞和中性粒细胞免疫细胞数量的变异性。
结果表明，接受芬戈莫德治疗的 RRMS 患者的总白细胞、中性粒细胞和淋巴细胞水平降低，但这些变化与月经周期阶段无关。在我们的研究中，健康个体的白细胞水平在增殖期明显低于其他阶段。
结果表明，接受芬戈莫德治疗的 RRMS 患者的淋巴细胞监测可以在月经周期的任何阶段进行。
